These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27038074)

  • 1. Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development.
    Kirsten N; Bulai Livideanu C; Richard MA; Konstantinou MP; Khemis A; Balluteaud C; Goujon C; Beylot-Barry M; Paul C;
    Br J Dermatol; 2016 Sep; 175(3):636-8. PubMed ID: 27038074
    [No Abstract]   [Full Text] [Related]  

  • 2. The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
    Tabolli S; Giannantoni P; Paradisi A; Abeni D
    Br J Dermatol; 2015 Jul; 173(1):256-8. PubMed ID: 25422080
    [No Abstract]   [Full Text] [Related]  

  • 3. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.
    Masson Regnault M; Castañeda-Sanabria J; Diep Tran MHT; Beylot-Barry M; Bachelez H; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Mahé E; Richard MA; Viguier M; Tubach F; Sbidian E; Paul C;
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):293-300. PubMed ID: 31419355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching biological agents for psoriasis in secondary care: a single-centre, retrospective, open-label study.
    Woo WA; Waite A; Rustin MH; McBride SR
    Br J Dermatol; 2014 Apr; 170(4):989-90. PubMed ID: 24298875
    [No Abstract]   [Full Text] [Related]  

  • 5. New treatments in psoriasis.
    Carrascosa JM
    Med Clin (Barc); 2017 Aug; 149(4):157-159. PubMed ID: 28476451
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of malignancy in psoriatic patients: Our clinical experience.
    Magnano M; Loi C; Sechi A; Sgubbi P; Raone B; Patrizi A; Bardazzi F
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28211641
    [No Abstract]   [Full Text] [Related]  

  • 7. Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review.
    Schaap MJ; van Winden MEC; Seyger MMB; de Jong EMGJ; Lubeek SFK
    J Am Acad Dermatol; 2020 Aug; 83(2):412-424. PubMed ID: 31369769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
    Strober B; Zhao Y; Tran MH; Gnanasakthy A; Nyirady J; Papavassilis C; Nelson LM; McLeod LD; Mordin M; Gottlieb AB; Elewski BE; Lebwohl M
    Int J Dermatol; 2016 Mar; 55(3):e147-55. PubMed ID: 26518255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
    Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
    J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brodalumab versus ustekinumab in psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
    [No Abstract]   [Full Text] [Related]  

  • 11. Brodalumab (Siliq
    Gupta AK; Versteeg SV; Abramovits W; Vincent KD
    Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
    [No Abstract]   [Full Text] [Related]  

  • 12. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
    Reich K; Ortonne JP; Kerkmann U; Wang Y; Saurat JH; Papp K; Langley R; Griffiths CE
    Dermatology; 2010; 221(2):172-8. PubMed ID: 20628238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on TNF Inhibitors in Dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2016 Jun; 35(6 Suppl):S104-6. PubMed ID: 27537073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic.
    Bonifati C; Graceffa D; Lora V; Maiani E
    G Ital Dermatol Venereol; 2016 Dec; 151(6):596-602. PubMed ID: 26505567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).
    Chiricozzi A; Saraceno R; Novelli L; Fida M; Caso F; Scarpa R; Costa L; Perricone R; Romanelli M; Chimenti S; Chimenti MS
    Expert Opin Ther Pat; 2016 Jul; 26(7):757-66. PubMed ID: 27266423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversy trails adaptive clinical trials.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
    [No Abstract]   [Full Text] [Related]  

  • 18. The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials.
    Langley RG; Reich K
    Br J Dermatol; 2013 Dec; 169(6):1198-206. PubMed ID: 23937204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine in the treatment of psoriasis.
    Gulliver WP
    Cutis; 2000 Nov; 66(5):365-9. PubMed ID: 11107522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.